Jeffery L. Painter

2.5k citations

28 papers · 1.3k indexed · 2 hit papers · h-index 10

Molecular Biology
Genetics top 5%
Toxicology top 1%
Computational Theory and Mathematics top 5%
Immunology

Co-authors: Matthew R. Nelson John C. Whittaker Pak C. Sham Aris Floratos Lon R. Cardon Paola Nicoletti Judong Shen Junwen Wang
Topics: Pharmacovigilance and Adverse Drug Reactions (12 papers)Biomedical Text Mining and Ontologies (4 papers)Biosimilars and Bioanalytical Methods (4 papers)
Cited by: Toxicology Genetics Health Informatics
Journals: Nature Nature GeneticsSHILAP Revista de lepidopterología
Partner nations: United States United Kingdom Japan

In The Last Decade

Jeffery L. Painter

25 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The support of human genetic evidence for approved drug indications

2015 874 citations Matthew R. Nelson, Jeffery L. Painter et al. profile →
Refining the impact of genetic evidence on clinical success

2024 80 citations Eric Vallabh Minikel, Jeffery L. Painter et al. Nature profile →

Peers

Countries citing papers authored by Jeffery L. Painter

Since Specialization

Citations

This map shows the geographic impact of Jeffery L. Painter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffery L. Painter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffery L. Painter more than expected).

Fields of papers citing papers by Jeffery L. Painter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffery L. Painter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffery L. Painter. The network helps show where Jeffery L. Painter may publish in the future.

Co-authorship network of co-authors of Jeffery L. Painter

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffery L. Painter. A scholar is included among the top collaborators of Jeffery L. Painter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffery L. Painter. Jeffery L. Painter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The need for guardrails with large language models in pharmacovigilance and other medical safety critical settings 2025 ·Scientific Reports ·Joe B. Hakim,Jeffery L. Painter,(unknown),(unknown),(unknown),(unknown),(unknown),Andrew Bate,Andrew L. Beam	1
2	Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks? 2025 ·Therapeutic Advances in Drug Safety ·Jeffery L. Painter,(unknown),Andrew Bate	3
3	Orchestrating generative AI in pharmacovigilance: predicting and preempting the unpredictable 2025 ·Therapeutic Advances in Drug Safety ·(unknown),Jeffery L. Painter,(unknown),Michael Gläser,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	0
4	Automating pharmacovigilance evidence generation: using large language models to produce context-aware structured query language 2024 ·JAMIA Open ·Jeffery L. Painter,(unknown),(unknown),Andrew Bate	6
5	Refining the impact of genetic evidence on clinical successbreakdown → 2024 ·Nature ·Eric Vallabh Minikel,Jeffery L. Painter,(unknown),Matthew R. Nelson	80
6	MSR20 NLP and Machine Learning to Automate Identification of Suspected Medication Errors from Real World Unstructured Narratives 2023 ·Value in Health ·Jeffery L. Painter,François Haguinet,(unknown),Andrew Bate	1
7	An industry perspective on the use of machine learning in drug and vaccine safety 2023 ·SHILAP Revista de lepidopterología ·Jeffery L. Painter,(unknown),Andrew Bate	6
8	Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software 2023 ·Frontiers in Digital Health ·Mala K. Talekar,Jeffery L. Painter,(unknown),(unknown),(unknown)	1
9	Identifying Barriers to Enrollment in Patient Pregnancy Registries: Building Evidence Through Crowdsourcing 2022 ·JMIR Formative Research ·Jeanne M. Pimenta,Jeffery L. Painter,(unknown),Roger A. Levy,Marcy Powell,(unknown),(unknown)	0
10	Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review 2022 ·Drug Safety ·Benjamin Kompa,Joe B. Hakim,Anil Palepu,(unknown),Michael R. Smith,Paul Bain,Stephen Woloszynek,Jeffery L. Painter,Andrew Bate,Andrew L. Beam	41
11	Engaging Patients via Online Healthcare Fora: Three Pharmacovigilance Use Cases 2022 ·Frontiers in Pharmacology ·(unknown),(unknown),Jeffery L. Painter,(unknown),(unknown),Andrew Bate	4
12	Developing Crowdsourced Training Data Sets for Pharmacovigilance Intelligent Automation 2020 ·Drug Safety ·(unknown),Andrew Bate,Jeffery L. Painter,(unknown),Gregory Powell	9
13	Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis 2017 ·JMIR Public Health and Surveillance ·(unknown),(unknown),Michael Gilbert,Julie Davidson,(unknown),Monica J. Barratt,(unknown),Jeffery L. Painter,(unknown),(unknown),Nabarun Dasgupta	33
14	Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases 2016 ·Drug Safety ·Suzie Seabroke,Gianmario Candore,Kristina Juhlin,(unknown),A Wisniewski,Ramin B. Arani,Jeffery L. Painter,(unknown),G. Niklas Norén,Jim Slattery	43
15	Social Media Listening for Routine Post-Marketing Safety Surveillance 2016 ·Drug Safety ·Gregory Powell,Harry Seifert,Tjark Reblin,(unknown),(unknown),J. Alan Menius,Jeffery L. Painter,(unknown),Carrie E. Pierce,Harold Rodriguez,John S. Brownstein,Clark C. Freifeld,(unknown),Nabarun Dasgupta	66
16	Impact of Subgroup Analyses and Adjustment by Stratification on Safety Signal Detection for Individual Case Reports 2014 ·Pharmacoepidemiology and Drug Safety ·Suzie Seabroke,Kristina Juhlin,Gianmario Candore,A Wisniewski,(unknown),Jeffery L. Painter,Daniel Soeria‐Atmadja,Phil Tregunno,G. Niklas Norén,Jim Slattery	0
17	Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations 2012 ·Drug Safety ·Xiwu Lin,Daniel Parks,Jeffery L. Painter,Christine M. Hunt,Heide A. Stirnadel-Farrant,Jie Cheng,(unknown),Kwan Lee	11
18	Containing the Cloud: Security Issues in a Large Scale Observational Pharmacovigilance Research Project. 2010 ·Security and Management ·Jeffery L. Painter	1
19	Toward Automating an Inference Model on Unstructured Terminologies: OXMIS Case Study 2010 ·Advances in experimental medicine and biology ·Jeffery L. Painter	2
20	Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases 2010 ·Journal of the American Medical Informatics Association ·Stephanie J. Reisinger,Patrick Ryan,Donald J. O’Hara,Gregory Powell,Jeffery L. Painter,Edward N. Pattishall,Jonathan Morris	76

About Jeffery L. Painter

Jeffery L. Painter is a scholar working on Toxicology, Health Informatics and Pharmacology, having authored 28 papers that have together received 1.3k indexed citations. Recurring topics across this work include Pharmacovigilance and Adverse Drug Reactions (12 papers), Biomedical Text Mining and Ontologies (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). The work is most often cited by research in Toxicology (147 citations), Genetics (394 citations) and Health Informatics (18 citations). Jeffery L. Painter has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Matthew R. Nelson, John C. Whittaker, Pak C. Sham, Aris Floratos, Lon R. Cardon, Paola Nicoletti, Judong Shen, Junwen Wang, Mulin Jun Li and Hannah Tipney. Their work appears in journals such as Nature, Nature Genetics and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact